The follow through to see it through
Whether we start from drug discovery or pick up an opportunity mid-pipeline, our team’s seamless coordination across functions and unwavering focus on transforming patients’ lives enable us to advance product candidates at any stage.
Product Pipeline
Nontuberculous Mycobacterial (NTM) Lung Disease
| Preclinical | Phase 1 | Phase 2 | Phase 3 | Approved |
ARIKAYCE® (Amikacin Liposome Inhalation Suspension)*
Refractory NTM: M. avium complex (MAC)
Approved
Nontuberculous mycobacterial (NTM) lung disease is a rare and serious disorder most commonly caused by a group of bacteria called Mycobacterium avium complex (MAC).1 People who have bronchiectasis, COPD, and asthma are at greater risk of getting NTM lung disease.2,3,4
ARIKAYCE® (Amikacin Liposome Inhalation Suspension) Lifecycle Management
Front Line Label Expansion
Phase 3
Nontuberculous mycobacterial (NTM) lung disease is a rare and serious disorder most commonly caused by a group of bacteria called Mycobacterium avium complex (MAC).1 People who have bronchiectasis, COPD, and asthma are at greater risk of getting NTM lung disease.2,3,4
Neutrophil-driven Inflammatory Conditions
| Preclinical | Phase 1 | Phase 2 | Phase 3 | Approved |
Brensocatib: DPP1 Inhibitor
Non-Cystic Fibrosis Bronchiectasis
Phase 3
Non-cystic fibrosis bronchiectasis (NCFBE) is a chronic pulmonary disorder in which the bronchi become permanently dilated due to a vicious cycle of inflammation and complications from prior infections.5,6 The condition is marked by frequent pulmonary exacerbations requiring antibiotic therapy and/or hospitalizations.
Brensocatib: DPP1 Inhibitor
Cystic Fibrosis
Phase 2
Cystic fibrosis (CF) is a rare, progressive, genetic disease that causes persistent lung infections and limits the ability to breathe over time.7 CF is caused by mutations in the cystic fibrosis transmembrane regulator (CFTR) gene.8
Brensocatib: DPP1 Inhibitor
Chronic Rhinosinusitis without Nasal Polyps (CRS)
Phase 1
CRS without nasal polyps is a chronic inflammatory process of the mucus membranes inside the sinuses. The most common symptoms include a decreased sense of smell and facial pain.9
Brensocatib: DPP1 Inhibitor
Hidradenitis Suppurativa (HS)
Phase 1
HS is a chronic relapsing inflammatory disorder, characterized by painful, inflamed, and swollen lesions affecting hair follicles, often in the armpits, groin, and skin folds.10
Additional Rare Pulmonary Diseases
| Preclinical | Phase 1 | Phase 2 | Phase 3 | Approved |
Treprostinil Palmitil Inhalation Powder
Pulmonary Hypertension associated with Interstitial Lung Diseases (PH-ILD)
Phase 2
Interstitial lung diseases (ILD) comprise a large group of diseases that cause fibrosis (scarring) of the lungs. Pulmonary hypertension (high blood pressure in the lungs) is a common and important complication of several ILDs that is associated with reduced exercise capacity and poor prognosis.12,13 PH-ILD is also known as WHO Group 3 Pulmonary Hypertension.
Treprostinil Palmitil Inhalation Powder
Pulmonary Arterial Hypertension (PAH)
Phase 2
Pulmonary arterial hypertension (PAH) is a serious, progressive, rare disease involving narrowing and constriction of the pulmonary arteries that carry blood from the right side of the heart to the lungs.11 PAH is also known as WHO Group 1 Pulmonary Hypertension.
Translational Medicine
| Preclinical | Phase 1 | Phase 2 | Phase 3 | Approved |
Translational Medicine
Multiple indications
Preclinical
We conduct research in-house to potentially bring forth new medicines and technologies that address rare and serious diseases.
* In the U.S., as a condition of accelerated approval, Insmed is conducting an additional clinical study to support full approval. Full approved has been granted in Europe and Japan.
References
- Adjemian J, Prevots DR, Gallagher J, Heap K, Gupta R, Griffith D. Lack of adherence to evidence-based treatment guidelines for nontuberculous mycobacterial lung disease. Ann Am Thorac Soc. 2014;11(1):9-16.
- Mirsaeidi M, Hadid W, Ericsoussi B, Rodgers D, Sadikot RT. Non-tuberculous mycobacterial disease is common in patients with non-cystic fibrosis bronchiectasis. Int J Infect Dis.2013;17(11):e1000-e1004.
- Andréjak C, Nielsen R, Thomsen VØ, Duhaut P, Sørensen HT, Thomsen RW. Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis. Thorax. 2013;68(3):256-262.
- Fritscher LG, Marras TK, Bradi AC, Fritscher CC, Balter MS, Chapman KR. Nontuberculous mycobacterial infection as a cause of difficult-to-control asthma: a case-control study. Chest. 2011;139(1):23-27.
- Prevalence and incidence of noncystic fibrosis bronchiectasis among US adults in 2013 (Weycker). https://www.ncbi.nlm.nih.gov/pubmed/28555504. Accessed December 2020.
- Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity (Flume). https://www.ncbi.nlm.nih.gov/pubmed/30215383. Accessed December 2020.
- Cystic Fibrosis Foundation. About Cystic Fibrosis. https://www.cff.org/What-is-CF/About-Cystic-Fibrosis/. Accessed December 2020.
- National Institutes of Health. Genetic and Rare Disease Information Center. https://rarediseases.info.nih.gov/diseases/6233/cystic-fibrosis. Accessed October 2020
- Cho SH, Kim DW, Gevaert P. Chronic Rhinosinusitis without Nasal Polyps. J Allergy Clin Immunol Pract. 2016 ; 4(4): 575–582.
- Phan K, Charlton O, Smith SD. Global Prevalence of Hidradenitis Suppurative and Geographical Variation—Systematic Review and Meta-Analysis. Phan et al. Biomedical Dermatology (2020) 4:2.
- Pulmonary Hypertension Association. About Pulmonary Hypertension. https://phassociation.org/types-pulmonary-hypertension-groups/. Accessed February 18, 2022. Accessed January 2021.
- American Lung Association. Interstitial Lung Disease. https://www.lung.org/lung-health-diseases/lung-disease-lookup/interstitial-lung-disease. Accessed January 2021.
- Caminati A. Pulmonary hypertension in chronic interstitial lung diseases. European Respiratory Review 2013 22: 292-301 https://err.ersjournals.com/content/22/129/292. Accessed January 2021.
